TABLE 2

Unadjusted serum bactericidal activity geometric mean titers against serogroups A, C, W, and Y prevaccination and at 7 and 28 days after a single dose of MenACWY-CRM conjugate or a single dose of MenACWY-PS polysaccharide vaccinea

SerogroupStudy groupPrevaccination hSBA GMT (95% CI)Day 7 hSBA GMT (95% CI)Day 28 hSBA GMT (95% CI)
AMenACWY-CRM3.2 (2.6, 4.0) [n = 75]4.3 (3.2, 5.7) [n = 72]16.7 (10.9, 26.1) [n = 71]
MenACWY-PS3.9 (3.0, 5.1) [n = 75]5.9 (4.2, 8.3) [n = 73]26.5 (16.1, 43.5) [n = 75]
CMenACWY-CRM6.3 (4.6, 8.5) [n = 73]14.3 (9.7, 21.3) [n = 71]32.7 (20.1, 53.2) [n = 68]
MenACWY-PS11.1 (8.2, 15.0) [n = 75]27.0 (18.8, 38.6) [n = 74]98.9 (64.9, 150.6) [n = 75]
WMenACWY-CRM12.0 (8.0, 18.0) [n = 75]20.67 (13.4, 31.8) [n = 68]64.1 (40.7, 100.8) [n = 66]
MenACWY-PS26.2 (17.5, 39.3) [n = 74]34.5 (23.4, 50.7) [n = 73]53.1 (35.6, 79.0) [n = 74]
YMenACWY-CRM3.8 (3.0, 4.7) [n = 75]5.5 (4.1, 7.5) [n = 70]15.4 (10.1, 23.5) [n = 71]
MenACWY-PS5.6 (4.2, 7.5) [n = 75]9.8 (7.1, 13.7) [n = 74]21.7 (13.9, 33.8) [n = 75]
  • a Abbreviations: hSBA, human complement source serum bactericidal activity; GMT, geometric mean titers; CI, confidence intervals. 95% confidence intervals are shown in parentheses, and numbers of samples are shown in square brackets. The numbers of samples at each time point differed due to missed visits, participant dropout, insufficient serum for assays, or failed assays.